Table 3.
Comparison of initial clinical and biological characteristics between patients with InR and CoR at 1 year and at last follow-up
| Characteristics | At 1 year |
At last follow-up |
||||
|---|---|---|---|---|---|---|
| CoR (n = 11) | InR (n = 34) | P value | CoR (n = 14) | InR (n = 24) | P value | |
| Female sex | 4 (36%) | 19 (56%) | 0.26 | 7 (50%) | 13 (54%) | 0.80 |
| Age (yr) | 11.9 (7.2–15.9) | 13.9 (8.6–15.6) | 0.38 | 10.8 (7.2–15.9) | 13.9 (8.6–15.6) | 0.06 |
| At diagnosis | ||||||
| Creatininemia (μmol/l) | 136 (82–727) | 231 (90–1110) | 0.01 | 134 (82–386) | 226.5 (90–1110) | 0.05 |
| eGFR (ml/min per 1.73 m2) | 42 (±15.6) | 29.8 (±15.4) | 0.03 | 37.8 (±16.7) | 28.9 (±14.8) | 0.10 |
| eGFR >30 ml/min per 1.73 m2 | 9 (82%) | 14 (42%) | 0.02 | 8 (57%) | 10 (42%) | 0.36 |
| eGFR <30 ml/min per 1.73 m2 | 2 (18%) | 20 (59%) | 0.02 | 6 (43%) | 14 (58%) | 0.36 |
| Hemoglobin (g/dl) | 10 (±1.5) | 10.6 (±1.7) | 0.29 | 10.5 (±1.5) | 10.4 (±1.9) | 0.84 |
| CRP (mg/l) | 14 (2–82) | 30 (2–161) | 0.08 | 39.5 (2–137) | 22.7 (2–161) | 0.35 |
| ESR (mm/h) | 62.2 (±25.7) | 72.1 (±29) | 0.48 | 71 (±26.1) | 70.6 (±31.7) | 0.97 |
| Albuminemia (g/l) | 41.1 (±4.5) | 37.3 (±4.6) | 0.03 | |||
| Uveitis complications | 1 (9%) | 8 (24%) | 0.65 | 2 (14%) | 6 (25%) | 0.35 |
| Granuloma on kidney biopsy | 3 (27%) | 4 (12%) | 0.32 | 5 (36%) | 1 (4%) | 0.02 |
| Fibrosis on kidney biopsy | 6 (55%) | 13 (38%) | 0.59 | 6 (43%) | 10 (42%) | 1.00 |
| Occurrence of uveitis after TIN | 5 (45%) | 20 (59%) | 0.72 | 4 (29%) | 18 (75%) | <0.01 |
| Progression | ||||||
| Methylprednisolone pulses | 2 (18%) | 17 (50%) | 0.09 | 5 (36%) | 10 (42%) | 0.72 |
| Second-line therapy | 3 (27%) | 9 (27%) | 1.00 | 4 (29%) | 5 (21%) | 0.70 |
| Kidney relapses | 0 (0%) | 5 (15%) | 0.31 | 2 (14%) | 3 (13%) | 1.00 |
| Uveitis relapses | 6 (55%) | 19 (56%) | 1.00 | 12 (86%) | 10 (42%) | <0.01 |
| Ophthalmologic involvement at 1 year | 4 (36%) | 10 (29%) | 0.72 | 6 (43%) | 4 (17%) | 0.13 |
| Ophthalmologic involvement at last follow-up | 4 (29%) | 7 (29%) | 1.00 | |||
| Treatmenta at 1 year | 6 (55%) | 17 (50%) | 0.79 | 7 (50%) | 14 (58%) | 0.62 |
| Treatmenta at last follow-up | 4 (29%) | 4 (17%) | 0.43 | |||
| Median time to follow-up (yr) | 3.2 (1.1–8.3) | 2.5 (1.2–9.5) | 0.23 | |||
CoR, complete recovery, InR, incomplete recovery, eGFR, estimated glomerular filtration rate, ESR, erythrocyte sedimentation rate, TIN, tubulointerstitial nephritis.
Data presented as median and rank (minimum and maximum), mean ± SD, or number and percentage.
a
Corticotherapy or second-line therapy.